Factors Influencing Viral Clearance in Mild COVID-19 and Clinical Characteristics of Asymptomatic Patients
Table 2
Treatments and clinical outcomes.
Total
Mildly symptomatic
Total confirmed SARS-COV-2
Viral clearance
Viral persistence
value
Symptomatic
Asymptomatic
value
Treatments
Antibiotics
38 (45.8%)
14 (41.2%)
20 (58.8%)
0.190
35 (48.6%)
3 (27.3%)
0.186
Treatments
0.239
0.092
Two medicines
6 (7.2%)
2 (5.7%)
3 (8.3%)
5 (7.0%)
1 (9.0%)
Two medicines + TCM
70 (84.3%)
33 (94.3%)
30 (83.3%)
63 (87.5%)
7 (63.6%)
Two medicines+ribavirin+TCM
6 (7.2%)
0
3 (8.3%)
3 (4.2%)
3 (27.3%)
Lopinavir/ritonavir medicine
81 (97.6%)
35 (100%)
35 (97.2%)
1.000
71 (98.6%)
10 (90.9%)
0.249
Oseltamivir
11 (13.4%)
2 (5.7%)
8 (22.2%)
0.085
10 (13.9%)
1 (9.0%)
1.000
Corticosteroid
23 (27.7%)
8 (22.9%)
12 (33.3%)
0.327
21 (29.2%)
2 (18.2%)
0.719
Intravenous immunoglobulin
6 (7.2%)
3 (8.6%)
2 (5.6%)
0.674
6 (8.3%)
0
1.000
Nasal oxygen therapy
46 (55.4%)
18 (51.4%)
20 (55.6%)
0.727
39 (54.2%)
7 (63.6%)
0.747
TCM
80 (96.4%)
34 (97.1%)
35 (97.2%)
1.000
70 (97.2%)
10 (90.9%)
0.351
Clinical outcomes
Time from the illness onset to admission
5 (2-7)
3 (2-5)
7 (5-9)
≤0.001
Time from the illness onset to diagnosis (days)
4.5 (2-7)
3 (1-5)
7 (4-9)
≤0.001
Time from illness to viral clearance (days)
16 (13-18)
13 (12-14)
18 (17-20.75)
≤0.001
Duration from illness to radiologic recovery (days)
15 (11-18)
11 (9.25-15)
17 (14-19)
≤0.001
Duration of lopinavir/ritonavir therapy (days)
10 (10-11)
10 (10-11)
11 (10-11)
0.181
11 (10-11)
10 (6-11)
0.229
Hospital length of stay (days)
16 (14-19)
15 (13-16%)
16 (18-21%)
≤0.001
16 (14-18)
18 (14-22)
0.246
Data are median (IQR) or (%). values were calculated by the Mann-Whitney test, test, or Fisher’s exact test, as appropriate. Two medicines: INF alpha-2b inhale+lopinavir/ritonavir; TCM: traditional Chinese medicine.
